The safety and performance of the Spectra Optia apheresis system platelet depletion protocol in patients with elevated platelet counts

Autor: Pamela Lopert, Sohair Abdelrahman, Christopher A. Graybill, Jack Rhodes, Betina Sørensen, Ming Li, Yu Hu, Depei Wu, Ligen Liu, Pengcheng He, Xuejun Zhang, Fen Huang, Jianda Hu, Jerry Bill

Publikováno v: Lopert, P, Abdelrahman, S, Graybill, C A, Rhodes, J, Sørensen, B, Li, M, Hu, Y, Wu, D, Liu, L, He, P, Zhang, X, Huang, F, Hu, J & Bill, J 2022, ' The safety and performance of the Spectra Optia apheresis system platelet depletion protocol in patients with elevated platelet counts ', Journal of Clinical Apheresis, vol. 37, no. 6, pp. 544-552 . https://doi.org/10.1002/jca.22009

Background: Thrombocytosis is a presenting and progressive clinical feature found in multiple disease states. It is characterized by high platelet (PLT) counts (>450 × 109/L) and can lead to thrombohemorrhagic events. Thrombocytapheresis or platelet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc710c7edf5c0f9e40719877f689209d
https://doi.org/10.1002/jca.22009

Safety and performance of the S pectra O ptia apheresis system for white blood cell depletion in patients with elevated white blood cell counts

Autor: Pamela Lopert, Sohair Abdelrahman, Christopher A. Graybill, Jack Rhodes, Daan Dierickx, Richard Schäfer, Marienn Reti, Depei Wu, Yu Hu, Fen Huang, Jianda Hu, Pengcheng He, Ligen Liu, Ming Li, Xuejun Zhang, Jerry Bill

Publikováno v: Journal of Clinical Apheresis.

BACKGROUND: For the past 30 years, white blood cell depletion (WBCD) or leukocytapheresis has been conducted to rapidly reduce excessive circulating white blood cell (WBC) concentrations in patients at risk for or with symptoms of leukostasis due to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f66141c5a737d93e78c7b1aec2ee8be
https://doi.org/10.1002/jca.22038

Inhibition of endothelin-1 with darusentan: a novel antihypertensive approach for the treatment of resistant hypertension

Autor: Christopher A Graybill, Robert G. Weiss, Marshelle Warren, Jennifer V. Linseman

Publikováno v: Therapy. 5:739-750

Darusentan is an ETA-selective endothelin receptor antagonist that is currently in Phase III clinical development for the treatment of resistant hypertension (RHTN). Current hypertension treatment guidelines describe RHTN as the failure to achieve go

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::972fbe91de44ea2b0ab4547021ea5362
https://doi.org/10.2217/14750708.5.6.739

Cooperative Nucleotide Binding to the Human Erythrocyte Sugar Transporter

Autor: Christopher A. Graybill, Anthony Carruthers, Kara B. Levine, Erin K. Cloherty

Publikováno v: Biochemistry. 41:12639-12651

The human erythrocyte glucose transport protein (GluT1) is an adenine nucleotide binding protein. When complexed with cytosolic ATP, GluT1 exhibits increased affinity for the sugar export site ligand cytochalasin B, prolonged substrate occlusion, red

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f426bfa92850b04cddbb1e218bcdea95
https://doi.org/10.1021/bi0259002